nach oben

Heart Failure Reviews

Erschienen in:

01.03.2014

Fibrosis and heart failure

verfasst von: Ana Maria Segura, O. H. Frazier, L. Maximilian Buja

Erschienen in: Heart Failure Reviews | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The extracellular matrix (ECM) is a living network of proteins that maintains the structural integrity of the myocardium and allows the transmission of electrical and mechanical forces between the myocytes for systole and diastole. During ventricular remodeling, as a result of iterations in the hemodynamic workload, collagen, the main component of the ECM, increases and occupies the areas between the myocytes and the vessels. The resultant fibrosis (reparative fibrosis) is initially a compensatory mechanism and may progress adversely influencing tissue stiffness and ventricular function. Replacement fibrosis appears at sites of previous cardiomyocyte necrosis to preserve the structural integrity of the myocardium, but with the subsequent formation of scar tissue and widespread distribution, it has adverse functional consequences. Continued accumulation of collagen impairs diastolic function and compromises systolic mechanics. Nevertheless, the development of fibrosis is a dynamic process wherein myofibroblasts, the principal cellular elements of fibrosis, are not only metabolically active and capable of the production and upregulation of cytokines but also have contractile properties. During the process of reverse remodeling with left ventricular assist device unloading, cellular, structural, and functional improvements are observed in terminal heart failure patients. With the advent of anti-fibrotic pharmacologic therapies, cellular therapy, and ventricular support devices, fibrosis has become an important therapeutic target in heart failure patients. Herein, we review the current concepts of fibrosis as a main component of ventricular remodeling in heart failure patients. Our aim is to integrate the histopathologic process of fibrosis with the neurohormonal, cytochemical, and molecular changes that lead to ventricular remodeling and its physiologic consequences in patients. The concept of fibrosis as living scar allows us to envision targeting this scar as a means of improving ventricular function in heart failure patients.

Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, Friedl A, Bleese N (1991) Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 83(2):504–514PubMed

Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13(7):1637–1652PubMed

Weber KT (2000) Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation 102(12):1342–1345PubMed

Schaper J, Meiser E, Stammler G (1985) Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ Res 56(3):377–391PubMed

Kostin S, Hein S, Arnon E, Scholz D, Schaper J (2000) The cytoskeleton and related proteins in the human failing heart. Heart Fail Rev 5(3):271–280. doi:10.1023/A:1009813621103 PubMed

Sharov VG, Kostin S, Todor A, Schaper J, Sabbah HN (2005) Expression of cytoskeletal, linkage and extracellular proteins in failing dog myocardium. Heart Fail Rev 10(4):297–303. doi:10.1007/s10741-005-7544-2 PubMed

Brilla CG, Weber KT (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26(7):671–677PubMed

Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83(6):1849–1865PubMed

Gandhi MS, Kamalov G, Shahbaz AU, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT (2011) Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart Fail Rev 16(1):23–34. doi:10.1007/s10741-010-9169-3 PubMedCentralPubMed

10.

Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87(4):1285–1342. doi:10.1152/physrev.00012.2007 PubMed

11.

Booz GW, Baker KM (1995) Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 30(4):537–543PubMed

12.

Ju H, Dixon IM (1996) Extracellular matrix and cardiovascular diseases. Can J Cardiol 12(12):1259–1267PubMed

13.

Sun Y, Weber KT (1998) Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 30(Suppl 1):3–8PubMed

14.

Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV et al (1992) Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20(1):3–16PubMed

15.

Medugorac I, Jacob R (1983) Characterisation of left ventricular collagen in the rat. Cardiovasc Res 17(1):15–21PubMed

16.

Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT (1995) Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 76(13):8D–13DPubMed

17.

Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96(11):4065–4082PubMed

18.

Badenhorst D, Maseko M, Tsotetsi OJ, Naidoo A, Brooksbank R, Norton GR, Woodiwiss AJ (2003) Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res 57(3):632–641PubMed

19.

Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ (1997) Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96(6):1991–1998PubMed

20.

Brower GL, Janicki JS (2001) Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 280(2):H674–H683PubMed

21.

Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107(7):984–991PubMed

22.

Lopez B, Gonzalez A, Diez J (2010) Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121(14):1645–1654. doi:10.1161/CIRCULATIONAHA.109.912774 PubMed

23.

Sun Y, Kiani MF, Postlethwaite AE, Weber KT (2002) Infarct scar as living tissue. Basic Res Cardiol 97(5):343–347. doi:10.1007/s00395-002-0365-8 PubMed

24.

Sun Y, Weber KT (2000) Infarct scar: a dynamic tissue. Cardiovasc Res 46(2):250–256PubMed

25.

Willems IE, Havenith MG, De Mey JG, Daemen MJ (1994) The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 145(4):868–875PubMed

26.

Sappino AP, Schurch W, Gabbiani G (1990) Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 63(2):144–161PubMed

27.

Skalli O, Schurch W, Seemayer T, Lagace R, Montandon D, Pittet B, Gabbiani G (1989) Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 60(2):275–285PubMed

28.

Piera-Velazquez S, Li Z, Jimenez SA (2011) Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 179(3):1074–1080. doi:10.1016/j.ajpath.2011.06.001 PubMed

29.

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13(8):952–961. doi:10.1038/nm1613 PubMed

30.

Bujak M, Frangogiannis NG (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74(2):184–195. doi:10.1016/j.cardiores.2006.10.002 PubMedCentralPubMed

31.

Leask A (2007) TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74(2):207–212. doi:10.1016/j.cardiores.2006.07.012 PubMed

32.

Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18(7):816–827. doi:10.1096/fj.03-1273rev PubMed

33.

Lijnen PJ, Petrov VV, Fagard RH (2000) Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71(1–2):418–435. doi:10.1006/mgme.2000.3032 PubMed

34.

Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, Mitchell JB, Biswal S, Channon KM, Wolin MS, Alp NJ, Paolocci N, Champion HC, Kass DA (2008) Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117(20):2626–2636. doi:10.1161/CIRCULATIONAHA.107.737031 PubMedCentralPubMed

35.

Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH (1993) Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88(6):2849–2861PubMed

36.

Xiao H, Zhang YY (2008) Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 35(3):335–341. doi:10.1111/j.1440-1681.2007.04876.x PubMed

37.

Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G (1993) Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122(1):103–111PubMed

38.

Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M (2000) Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58(5):1885–1892. doi:10.1111/j.1523-1755.2000.00360.x PubMed

39.

Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106(1):130–135

40.

Flanders KC (2004) Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85(2):47–64. doi:10.1111/j.0959-9673.2004.00377.x PubMedCentralPubMed

41.

Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358(20):2148–2159. doi:10.1056/NEJMra0800239 PubMed

42.

Anker SD, von Haehling S (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90(4):464–470PubMed

43.

El-Menyar AA (2008) Cytokines and myocardial dysfunction: state of the art. J Card Fail 14(1):61–74. doi:10.1016/j.cardfail.2007.09.006 PubMed

44.

Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N (2010) Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15(6):543–562. doi:10.1007/s10741-010-9168-4 PubMed

45.

Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91(11):988–998PubMed

46.

Petersen JW, Felker GM (2006) Inflammatory biomarkers in heart failure. Congest Heart Fail 12(6):324–328PubMed

47.

Satoh M, Minami Y, Takahashi Y, Nakamura M (2008) Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep 5(2):69–74PubMed

48.

von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD (2009) Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 5(4):549–560. doi:10.1016/j.hfc.2009.04.001

49.

Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L, Blackshear PJ, Carballo E, Sivasubramanian N, Mann DL (2002) Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 105(18):2192–2197PubMed

50.

Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Mohr R, Yakirevich V (1996) Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 28(1):247–252PubMed

51.

Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119(10):1386–1397. doi:10.1161/CIRCULATIONAHA.108.802918 PubMedCentralPubMed

52.

Nakano M, Knowlton AA, Dibbs Z, Mann DL (1998) Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 97(14):1392–1400PubMed

53.

Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115(11):1398–1407. doi:10.1161/CIRCULATIONAHA.106.643585 PubMed

54.

Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM (2004) Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 109(15):1892–1897. doi:10.1161/01.CIR.0000124227.00670.AB PubMed

55.

Wong GH, Goeddel DV (1988) Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242(4880):941–944PubMed

56.

Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, Spinale FG, Feuerstein G, Sivasubramanian N, Mann DL (2003) Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation 108(8):1002–1008. doi:10.1161/01.CIR.0000085203.46621.F4 PubMed

57.

Janczewski AM, Kadokami T, Lemster B, Frye CS, McTiernan CF, Feldman AM (2003) Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 284(3):H960–H969. doi:10.1152/ajpheart.00718.2001 PubMed

58.

Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL (1997) Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95(5):1247–1252PubMed

59.

Flesch M, Hoper A, Dell’Italia L, Evans K, Bond R, Peshock R, Diwan A, Brinsa TA, Wei CC, Sivasubramanian N, Spinale FG, Mann DL (2003) Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 108(5):598–604. doi:10.1161/01.CIR.0000081768.13378.BF PubMed

60.

Siwik DA, Colucci WS (2004) Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9(1):43–51. doi:10.1023/B:HREV.0000011393.40674.13 PubMed

61.

Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL (2001) Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104(7):826–831PubMed

62.

Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH (1995) Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91(1):161–170PubMed

63.

Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT (1988) Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 22(10):686–695PubMed

64.

Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT (1989) Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64(6):1041–1050PubMed

65.

Jugdutt BI (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108(11):1395–1403. doi:10.1161/01.CIR.0000085658.98621.49 PubMed

66.

Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ (2006) IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69(1):164–177. doi:10.1016/j.cardiores.2005.08.017 PubMed

67.

Maass DL, White J, Horton JW (2002) IL-1beta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma. Shock 18(4):360–366PubMed

68.

Chandrasekar B, Mummidi S, Claycomb WC, Mestril R, Nemer M (2005) Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 280(6):4553–4567. doi:10.1074/jbc.M411787200 PubMed

69.

Dai RP, Dheen ST, He BP, Tay SS (2004) Differential expression of cytokines in the rat heart in response to sustained volume overload. Eur J Heart Fail 6(6):693–703. doi:10.1016/j.ejheart.2003.11.014 PubMed

70.

Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S (1997) Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 81(5):664–671PubMed

71.

Yamauchi-Takihara K, Kishimoto T (2000) Cytokines and their receptors in cardiovascular diseases–role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol 81(1):1–16PubMedCentralPubMed

72.

Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG (1998) Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 274(5 Pt 2):H1516–H1523PubMed

73.

Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98(17):1728–1734PubMed

74.

Mann DL, Spinale FG (1998) Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 98(17):1699–1702PubMed

75.

Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82(4):482–495PubMed

76.

Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P (2005) Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3(3):221–229PubMedCentralPubMed

77.

Li YY, McTiernan CF, Feldman AM (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46(2):214–224PubMed

78.

Fedak PW, Verma S, Weisel RD, Li RK (2005) Cardiac remodeling and failure from molecules to man (Part II). Cardiovasc Pathol 14(2):49–60. doi:10.1016/j.carpath.2005.01.005 PubMed

79.

Stawowy P, Margeta C, Kallisch H, Seidah NG, Chretien M, Fleck E, Graf K (2004) Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res 63(1):87–97. doi:10.1016/j.cardiores.2004.03.010 PubMed

80.

Dostal DE, Baker KM (1999) The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85(7):643–650PubMed

81.

Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273–1292. doi:10.1111/j.1476-5381.2010.00750.x PubMed

82.

Raman VK, Lee YA, Lindpaintner K (1995) The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 76(13):18D–23DPubMed

83.

Gradman AH, Papademetriou V (2009) Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am Heart J 157(6 Suppl):S17–S23. doi:10.1016/j.ahj.2009.04.007 PubMed

84.

Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H (1996) Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR (mRen2)27 transgenic rats. Circulation 94(4):785–791PubMed

85.

Schnee JM, Hsueh WA (2000) Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46(2):264–268PubMed

86.

Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T (2002) TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109(6):787–796. doi:10.1172/JCI14190 PubMed

87.

Kumar R, Singh VP, Baker KM (2009) The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep 11(2):104–110PubMed

88.

Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86(3):747–803. doi:10.1152/physrev.00036.2005 PubMed

89.

Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A (1998) Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32(2):273–279PubMed

90.

Brilla CG (2000) Aldosterone and myocardial fibrosis in heart failure. Herz 25(3):299–306PubMed

91.

Grieve DJ, Shah AM (2003) Oxidative stress in heart failure. More than just damage. Eur Heart J 24(24):2161–2163PubMed

92.

Zimmet JM, Hare JM (2006) Nitroso-redox interactions in the cardiovascular system. Circulation 114(14):1531–1544PubMed

93.

Tsutsui H, Kinugawa S, Matsushima S (2008) Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 72(Suppl A):A31–A37PubMed

94.

Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81(3):449–456. doi:10.1093/cvr/cvn280 PubMed

95.

Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG (1999) Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 277(2 Pt 2):H777–H787PubMed

96.

Rabelink TJ, Luscher TF (2006) Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 26(2):267–271. doi:10.1161/01.ATV.0000196554.85799.77 PubMed

97.

Takimoto E, Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49(2):241–248. doi:10.1161/01.HYP.0000254415.31362.a7 PubMed

98.

Frazier OH, Gradinac S, Segura AM, Przybylowski P, Popovic Z, Vasiljevic J, Hernandez A, McAllister HA Jr, Bojic M, Radovancevic B (2000) Partial left ventriculectomy: which patients can be expected to benefit? Ann Thorac Surg 69(6):1836–1841PubMed

99.

Miner EC, Miller WL (2006) A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc 81(1):71–76. doi:10.4065/81.1.71 PubMed

100.

Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P (1994) Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89(1):151–163PubMed

101.

Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54(19):1747–1762. doi:10.1016/j.jacc.2009.05.015 PubMed

102.

Sun Y (2009) Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 81(3):482–490. doi:10.1093/cvr/cvn333 PubMed

103.

Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A (2004) Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64(3):526–535. doi:10.1016/j.cardiores.2004.07.017 PubMed

104.

Roy S, Khanna S, Bickerstaff AA, Subramanian SV, Atalay M, Bierl M, Pendyala S, Levy D, Sharma N, Venojarvi M, Strauch A, Orosz CG, Sen CK (2003) Oxygen sensing by primary cardiac fibroblasts: a key role of p21(Waf1/Cip1/Sdi1). Circ Res 92(3):264–271PubMed

105.

O’Riordan E, Mendelev N, Patschan S, Patschan D, Eskander J, Cohen-Gould L, Chander P, Goligorsky MS (2007) Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 292(1):H285–H294. doi:10.1152/ajpheart.00560.2006 PubMed

106.

Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H (2005) Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 111(19):2430–2437. doi:10.1161/01.CIR.0000165066.71481.8E PubMed

107.

Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 148(5):1639–1648PubMed

108.

Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA Jr (1991) Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 69(3):590–600PubMed

109.

Diez J, Gonzalez A, Lopez B, Querejeta R (2005) Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2(4):209–216. doi:10.1038/ncpcardio0158 PubMed

110.

Berk BC, Fujiwara K, Lehoux S (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117(3):568–575. doi:10.1172/JCI31044 PubMedCentralPubMed

111.

Diez J (2007) Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 9(7):546–550

112.

Diez J, Lopez B, Gonzalez A, Querejeta R (2001) Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 16(6):328–335PubMed

113.

Diez J (2009) Towards a new paradigm about hypertensive heart disease. Med Clin North Am 93(3):637–645. doi:10.1016/j.mcna.2009.02.002 PubMed

114.

Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343(19):1388–1398. doi:10.1056/NEJM200011093431908 PubMed

115.

Cooper LT Jr (2009) Myocarditis. N Engl J Med 360(15):1526–1538. doi:10.1056/NEJMra0800028 PubMed

116.

Liu P, Martino T, Opavsky MA, Penninger J (1996) Viral myocarditis: balance between viral infection and immune response. Can J Cardiol 12(10):935–943PubMed

117.

Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99(8):1091–1100PubMed

118.

Yajima T, Knowlton KU (2009) Viral myocarditis: from the perspective of the virus. Circulation 119(19):2615–2624. doi:10.1161/CIRCULATIONAHA.108.766022 PubMed

119.

Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB, Rose NR (2004) Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 165(6):1883–1894PubMed

120.

Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Steele RA, Gatewood SJ, Rose NR (2005) IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. J Immunol 174(1):261–269PubMed

121.

Kania G, Blyszczuk P, Stein S, Valaperti A, Germano D, Dirnhofer S, Hunziker L, Matter CM, Eriksson U (2009) Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor beta-mediated cardiac fibrosis in experimental autoimmune myocarditis. Circ Res 105(5):462–470. doi:10.1161/CIRCRESAHA.109.196287 PubMed

122.

Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101(19):2271–2276PubMed

123.

Ilercil A, Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Welty TK, Robbins DC, Fabsitz RR, Howard BV, Lee ET (2001) Relationship of impaired glucose tolerance to left ventricular structure and function: the strong heart study. Am Heart J 141(6):992–998. doi:10.1067/mhj.2001.115302 PubMed

124.

Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S (2000) Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 32(9):1621–1629. doi:10.1006/jmcc.2000.1197 PubMed

125.

Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P (2000) Myocardial cell death in human diabetes. Circ Res 87(12):1123–1132PubMed

126.

Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121(9):748–757. doi:10.1016/j.amjmed.2008.03.046 PubMed

127.

Zieman SJ, Kass DA (2004) Advanced glycation end product crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64(5):459–470PubMed

128.

Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101(8):899–907PubMed

129.

Tesfamariam B, Brown ML, Cohen RA (1991) Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87(5):1643–1648. doi:10.1172/JCI115179 PubMedCentralPubMed

130.

Brilla CG (2000) Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 46(2):324–331PubMed

131.

Wagman G, Fudim M, Kosmas CE, Panni RE, Vittorio TJ (2012) The neurohormonal network in the RAAS can bend before breaking. Curr Heart Fail Rep 9(2):81–91. doi:10.1007/s11897-012-0091-y PubMed

132.

Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575–1581PubMed

133.

Xu Y, Tang T, Ding Y, Yao R, Xie J, Liao M, Xiao H, Chen Y, Yu X, Fu M, Liao Y, Zhao G, Cheng X (2010) Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Am J Med Sci 340(2):121–127. doi:10.1097/MAJ.0b013e3181e2b353 PubMed

134.

Landmesser U, Wollert KC, Drexler H (2009) Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 81(3):519–527. doi:10.1093/cvr/cvn317 PubMed

135.

Gonzalez A, Ravassa S, Beaumont J, Lopez B, Diez J (2011) New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 58(18):1833–1843. doi:10.1016/j.jacc.2011.06.058 PubMed

136.

Bauersachs J (2010) Regulation of myocardial fibrosis by MicroRNAs. J Cardiovasc Pharmacol 56(5):454–459. doi:10.1097/FJC.0b013e3181ee81df PubMed

137.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224):980–984. doi:10.1038/nature07511 PubMed

138.

Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, Morine KJ, Gardner TJ, Discher DE, Sweeney HL (2006) Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol 290(6):H2196–H2203. doi:10.1152/ajpheart.01017.2005 PubMed

139.

Xu X, Xu Z, Xu Y, Cui G (2005) Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis 16(4):245–255PubMed

140.

Gnecchi M, Danieli P, Cervio E (2012) Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol 57(1):48–55. doi:10.1016/j.vph.2012.04.002 PubMed

141.

Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, Mendelsohn F, Chronos N, Haley R, Willerson JT, Annex BH (2011) A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovascul Interv Off J Soc Cardiac Angiogr Interv 78(7):1060–1067. doi:10.1002/ccd.23066

142.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD, Cardiovascular Cell Therapy Research N (2012) Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA J Am Med Assoc 307(16):1717–1726. doi:10.1001/jama.2012.418

143.

Xydas S, Rosen RS, Ng C, Mercando M, Cohen J, DiTullio M, Magnano A, Marboe CC, Mancini DM, Naka Y, Oz MC, Maybaum S (2006) Mechanical unloading leads to echocardiographic, electrocardiographic, neurohormonal, and histologic recovery. J Heart Lung Transpl Off Public Int Soc Heart Transpl 25(1):7–15. doi:10.1016/j.healun.2005.08.001

144.

Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D (1995) Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 91(11):2717–2720PubMed

145.

Nakatani S, McCarthy PM, Kottke-Marchant K, Harasaki H, James KB, Savage RM, Thomas JD (1996) Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol 27(4):894–901PubMed

146.

Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB (1998) Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98(7):656–662PubMed

147.

Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, Connelly JH, Koerner MM, Entman ME, Frazier OH, Noon GP, Torre-Amione G (2001) Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transpl Off Public Int Soc Heart Transpl 20(4):457–464

148.

Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G, LVAD Working Group (2007) Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD working group. Circulation 115(19):2497–2505. doi:10.1161/CIRCULATIONAHA.106.633180 PubMed

149.

Thohan V, Stetson SJ, Nagueh SF, Rivas-Gotz C, Koerner MM, Lafuente JA, Loebe M, Noon GP, Torre-Amione G (2005) Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transpl Off Public Int Soc Heart Transpl 24(5):566–575. doi:10.1016/j.healun.2004.02.017

150.

Bruggink AH, van Oosterhout MF, de Jonge N, Ivangh B, van Kuik J, Voorbij RH, Cleutjens JP, Gmelig-Meyling FH, de Weger RA (2006) Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transpl Off Public Int Soc Heart Transpl 25(9):1091–1098. doi:10.1016/j.healun.2006.05.011

151.

Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM (2001) Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104(10):1147–1152PubMed

152.

Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AH, Oz MC, D’Armiento J, Burkhoff D (2005) Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 112(3):364–374. doi:10.1161/CIRCULATIONAHA.104.515106 PubMed

153.

Drakos SG, Kfoury AG, Selzman CH, Verma DR, Nanas JN, Li DY, Stehlik J (2011) Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol 26(3):245–255. doi:10.1097/HCO.0b013e328345af13 PubMedCentralPubMed

154.

Burkhoff D, Klotz S, Mancini DM (2006) LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 12(3):227–239. doi:10.1016/j.cardfail.2005.10.012 PubMed

155.

Maybaum S, Kamalakannan G, Murthy S (2008) Cardiac recovery during mechanical assist device support. Semin Thorac Cardiovasc Surg 20(3):234–246. doi:10.1053/j.semtcvs.2008.08.003 PubMed

156.

Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A (2011) Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 123(4):381–390. doi:10.1161/CIRCULATIONAHA.109.933960 PubMed

157.

Birks EJ (2010) Myocardial recovery in patients with chronic heart failure: is it real? J Card Surg 25(4):472–477. doi:10.1111/j.1540-8191.2010.01051.x PubMed

158.

Segura AM, Frazier OH, Demirozu Z, Buja LM (2011) Histopathologic correlates of myocardial improvement in patients supported by a left ventricular assist device. Cardiovasc Pathol 20(3):139–145. doi:10.1016/j.carpath.2010.01.011 PubMed

Titel: Fibrosis and heart failure
verfasst von: Ana Maria Segura
O. H. Frazier
L. Maximilian Buja
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 2/2014
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-012-9365-4

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Fibrosis and heart failure

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

Physiologic and hematologic concerns of rotary blood pumps: what needs to be improved?

Could interferon-gamma be a therapeutic target for treating heart failure?

Angiotensin II, sympathetic nerve activity and chronic heart failure

Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and meta-analysis of individual patient data

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie